FDA Drug Regulatory Intelligence

Shortage: Ifosfamide Injection

This page indexes a United States Food and Drug Administration (FDA) drug-shortage record for Ifosfamide Injection. The record is reported by Hikma Pharmaceuticals Usa, Inc. and currently carries a regulatory status of Current. A drug-shortage entry of this kind is an administrative supply-status record that the FDA maintains and publishes for transparency and reference. This entry names the affected product as Ifosfamide Injection, attributes the report to the company shown above, and records a status of Current marking where the shortage sits within the agency's public tracking lifecycle at the time it was ingested by this site. The affected presentation is described in the source as Ifosfamide, Injection, 50 mg/1 mL (NDC 0143-9530-01). The availability field published by the FDA reads: This presentation is temporally on backorder.. This shortage record was published on 2026-06-12. It was first posted on 2026-06-12. All values shown here are reproduced as regulatory data points from the official FDA drug-shortages dataset to help you find and verify the original entry. This page does not advise on therapeutic substitution, does not assess clinical impact, and is not a recommendation of any kind. Verify the current status against the linked FDA source.

Source-derived regulatory summary

The text in this section is generated from the FDA source fields shown elsewhere on this page. It is regulatory information only — not medical advice — and adds no facts beyond the official record.

This record pertains to Ifosfamide Injection, a pharmaceutical product presented as an injection with a concentration of 50 mg per 1 mL. The National Drug Code (NDC) for this product is 0143-9530-01. The product is currently listed as being on backorder, with additional lots expected to be available in the June to July 2026 timeframe. The record is maintained by Hikma Pharmaceuticals Usa, Inc.

Regulatory context

The status 'Current' indicates that the product is actively listed and recognized by the FDA. However, the note regarding backorder signifies that it is temporarily unavailable for distribution. The initial posting and last updated dates reflect when the information was first recorded and last modified, respectively.

Fields used include generic_name, status, presentation, availability, company_name, related_info, initial_posting_date, and last_updated_date. No fields were absent.

FDA shortage data

Generic name Ifosfamide Injection
Status Current
Presentation Ifosfamide, Injection, 50 mg/1 mL (NDC 0143-9530-01)
Availability (source text) This presentation is temporally on backorder.
Reporting company Hikma Pharmaceuticals Usa, Inc.
Related information Additional lots will be available in the June – July 2026 timeframe. Product will be made available as it is released.
Initial posting date 2026-06-12
Last updated date 2026-06-12

How to interpret this shortage record

A drug-shortage record means the FDA has logged a reported supply constraint for a product as part of its public shortage tracking. The status (Current) describes where the shortage sits in its lifecycle according to the agency's data. A shortage entry is an administrative supply signal — it does not describe the clinical role of the product, does not suggest any substitute, and does not indicate that any specific patient is affected. Read this entry as a pointer to the official FDA shortage listing and confirm the live status there before relying on it.

What this record does not mean

This shortage record does not constitute medical advice and does not tell you whether to start, stop, switch, or avoid any product. It does not assess safety for any individual, does not provide dosage, treatment, or therapeutic guidance, and does not diagnose any condition. The dataset is coverage-limited: it reflects what the FDA has published in the indexed source at ingestion time, which may lag the live record and may omit details held only in primary documents. For any health decision, consult a qualified healthcare professional, and for the authoritative record consult the FDA directly through the linked official source.

Related manufacturer

This shortage is reported by Hikma Pharmaceuticals Usa Inc. That page aggregates the firm's other indexed records as coverage-limited regulatory signals (not quality ratings).

Related shortages (Current)

Source & provenance

Official source
https://www.accessdata.fda.gov/scripts/drugshortages/
Source dataset
openFDA Drug Shortages API
Publication date
2026-06-12
Ingested
2026-06-14
Record hash
b256233eb0a81e61

Verify every value against the official FDA source above. This site links to the regulator's record rather than replacing it.